Hologic, Inc. (NASDAQ:HOLX) Receives Average Recommendation of “Hold” from Brokerages

Hologic, Inc. (NASDAQ:HOLX) has been given an average recommendation of “Hold” by the eight ratings firms that are covering the firm, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $86.89.

A number of equities research analysts have issued reports on HOLX shares. UBS Group boosted their price target on Hologic from $78.00 to $79.00 and gave the company a “neutral” rating in a research note on Friday, February 2nd. William Blair reissued an “outperform” rating on shares of Hologic in a report on Friday, February 2nd. Raymond James boosted their price target on Hologic from $85.00 to $88.00 and gave the stock an “outperform” rating in a report on Friday, February 2nd. Needham & Company LLC boosted their price target on Hologic from $83.00 to $90.00 and gave the stock a “buy” rating in a report on Friday, February 2nd. Finally, StockNews.com cut Hologic from a “buy” rating to a “hold” rating in a report on Friday, March 8th.

Hologic Stock Performance

NASDAQ:HOLX opened at $77.96 on Friday. The company has a quick ratio of 3.18, a current ratio of 3.89 and a debt-to-equity ratio of 0.55. The stock has a market cap of $18.30 billion, a P/E ratio of 36.95, a price-to-earnings-growth ratio of 2.58 and a beta of 1.00. The firm’s fifty day simple moving average is $74.82 and its 200 day simple moving average is $71.88. Hologic has a twelve month low of $64.02 and a twelve month high of $87.88.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.98 EPS for the quarter, topping the consensus estimate of $0.95 by $0.03. Hologic had a return on equity of 18.91% and a net margin of 12.98%. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $989.32 million. During the same period last year, the company earned $1.07 EPS. Hologic’s revenue for the quarter was down 5.7% on a year-over-year basis. As a group, research analysts predict that Hologic will post 4.02 EPS for the current year.

Insiders Place Their Bets

In related news, Director Charles J. Dockendorff sold 1,465 shares of Hologic stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $76.21, for a total transaction of $111,647.65. Following the completion of the sale, the director now owns 1,572 shares of the company’s stock, valued at $119,802.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CFO Karleen Marie Oberton sold 14,940 shares of the company’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $75.00, for a total value of $1,120,500.00. Following the transaction, the chief financial officer now owns 103,916 shares of the company’s stock, valued at approximately $7,793,700. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Charles J. Dockendorff sold 1,465 shares of the stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $76.21, for a total value of $111,647.65. Following the transaction, the director now directly owns 1,572 shares in the company, valued at approximately $119,802.12. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 32,846 shares of company stock valued at $2,473,443. 1.75% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Hologic

Several large investors have recently bought and sold shares of the stock. Nomura Holdings Inc. purchased a new position in shares of Hologic in the 4th quarter valued at about $352,000. HighPoint Advisor Group LLC purchased a new position in shares of Hologic in the 4th quarter valued at about $492,000. PNC Financial Services Group Inc. increased its holdings in shares of Hologic by 0.9% in the 4th quarter. PNC Financial Services Group Inc. now owns 31,933 shares of the medical equipment provider’s stock valued at $2,282,000 after acquiring an additional 288 shares during the last quarter. Leo Wealth LLC acquired a new stake in shares of Hologic in the 4th quarter valued at about $322,000. Finally, SageView Advisory Group LLC acquired a new stake in shares of Hologic in the 4th quarter valued at about $289,000. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.